类风湿关节炎患者在甲氨蝶呤给药期间（MTX-LPD）的淋巴增殖性疾病中的免疫反应。
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
作者信息
Saito Shuntaro, Takeuchi Tsutomu
出版信息
J Clin Exp Hematop. 2019;59(4):145-155. doi: 10.3960/jslrt.19028.
Abstract
Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients.
摘要
甲氨蝶呤（MTX）是治疗类风湿关节炎（RA）的一线合成改善病情抗风湿药（DMARD）。虽然RA炎症本身会增加发生淋巴增殖性疾病（LPD）的风险，但观察到停用MTX后LPD会自发消退，这引发了MTX具有致淋巴瘤作用的理论。在本综述中，我们重点关注了RA患者在MTX治疗期间发生的LPD所涉及的几种免疫反应。
Zotero 插件